News for Genexine, Inc. (095700.KQ)

China's Foreseen Biotechnology out-licensed global rights for an ADC candidate to France’s Ipsen in a deal potentially worth over $1 billion. Read more here.

Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

The global Vaccine Adjuvants market size is expected to reach USD 2.90 billion by 2030 and exhibit a CAGR of 11.9% in the forecast period (2023−2030),...

Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer...

The triple-negative breast cancer market is witnessing significant growth and evolution due to increased awareness, technological advancements, therapeutic...

Rezolute, a biotech firm, trading at 50% of cash, is developing RZ358, a potential treatment for hyperinsulinism, with promising phase 3 study prospects.

First market approval for Genexine discovered and developed therapeutic drug, Efesa , a long-acting erythropoietin for the treatment of Chronic Kidney disease Induced anemia Label expansion...

The cervical dysplasia market is expected to grow significantly owing to an increased screening rate and increasing initiatives to create public awareness....

Explore groundbreaking insights on GenFleet and Verastem's innovations in the China biotech landscape. Click here for more with China Bio Today's latest article.

The cervical cancer market is expected to grow due to factors like an increase in the patient pool, rising awareness of the disease, an increase in...

Human Papillomavirus Associated Cancer Pipeline constitutes 50+ key companies continuously working towards developing 50+ Human Papillomavirus Associated...

As per DelveInsight, recent advances in Cervical Cancer have provided new options for treating patients with advanced forms of the disease, fulfilling a...

The current chemotherapy-dominated landscape of cervical cancer treatment is set to change to include multiple different drug classes. ...

/PRNewswire/ -- The